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Background and purpose   The Scandinavian Sarcoma Group 
(SSG) XIV protocol is based on experience from previous SSG 
trials and other osteosarcoma intergroup trials, and has been con-
sidered the best standard of care for patients with extremity local-
ized, non-metastatic osteosarcoma. We analyzed the outcome in 
63 consecutive patients.
Patients and methods   From 2001 through 2005, 63 patients 
recruited from centers in Sweden, Norway, and Finland were 
included. They received preoperative chemotherapy consisting of 
2 cycles of paired methotrexate (12 g/m2), cisplatin (90 mg/m2), 
and doxorubicin (75 mg/m2). 3 cycles were administered post-
operatively, and poor histological responders were given 3 addi-
tional cycles of ifosfamide (10–12 g/m2) as a salvage strategy. 
Results   With a median follow-up of 77 months for survivors, 
the estimated metastasis-free and sarcoma-related survival at 5 
years was 70% and 76%, respectively. 53 patients were treated 
with limb salvage surgery or rotationplasty and 2 patients experi-
enced a local recurrence. 3 toxic deaths were recorded, all related 
to acute toxicity from chemotherapy. The 5-year metastasis-free 
survival of poor histological responders receiving add-on treat-
ment with ifosfamide was 47%, as compared to 89% for good his-
tological responders. 
Interpretation   Outcome from the SSG XIV protocol com-
pares favorably with the results of previous SSG trials and other 
published osteosarcoma trials. However, salvage therapy given to 
poor responders did not improve outcome to a similar degree as 
for good responders. In a multi-institutional setting, more than 
four-fifths of the patients were operated with limb salvage surgery 
or rotationplasty, with few local recurrences.
 
Current management of high-grade osteosarcoma comprises 
pre- and postoperative chemotherapy and complete surgical 
removal of all tumor sites (Link et al. 1986, Fuchs et al. 1998, 
Bacci et al. 2000). With this strategy, 5-year overall survival 
rates of 70% have been reported for patients aged ≤ 40 years 
with non-metastatic, extremity localized osteosarcoma at 
diagnosis (Bielack et al. 2002, Smeland et al. 2003, Ferrari et 
al. 2005). Preoperative chemotherapy offers an opportunity to 
modify postoperative chemotherapy according to histological 
response. Although never proven to be effective in a random-
ized trial, this principle has been used in several osteosarcoma 
trials (Rosen et al. 1979, 1982, Winkler et al. 1988, Bacci et 
al. 1993).
The drugs active in osteosarcoma are doxorubicin, metho-
trexate, cisplatin, and ifosfamide, but there is still no consen-
sus on their optimal combination (Fuchs et al. 1998, Ferrari et 
al. 2005, Meyers et al. 2005, Lewis et al. 2007). In the SSG 
VIII study, all patients received a preoperative combination of 
methotrexate, doxorubicin, and cisplatin (Smeland et al. 2003). 
Poor responders were given an exchange to a combination of 
ifosfamide/etoposide postoperatively. 5-year metastasis-free 
and sarcoma-related survival was 63% and 74%, respectively. 
However, the ifosfamide/etoposide replacement resulted in 
poor outcome for poor responders. In the recent Italian/Scan-
dinavian ISG/SSG 1 protocol, the addition of high-dose ifos-
famide up-front to all patients failed to improve outcome (Fer-
rari et al. 2005). In a previous trial from the Rizzoli Institute, 
giving ifosfamide (9 g/m2) to poor responders had resulted in 
a similar outcome for both poor and good responders (Bacci 
et al. 1993). This, together with the COSS-86 study using the 212  Acta Orthopaedica 2011; 82 (2): 211–216
4 active drugs for all patients, probably represents the best sur-
vival data published (Fuchs et al. 1998). Thus, based on the 
SSG’s own experience and that of other intergroups, the SSG 
XIV protocol was considered  to be the best standard therapy 
in classical osteosarcoma. All patients received a 3-drug com-
bination of methotrexate, doxorubicin, and cisplatin (MAP) 
pre- and postoperatively and poor histological responders also 
received high-dose ifosfamide. A primary report on the SSG 
XIV protocol was published in the SSG 30-year anniversary 
report (Smeland et al. 2009). Here we report the results with a 
minimum follow-up of 4 years.
Patients and methods
Patients 
From March 2001 through April 2005, 71 consecutive patients 
with high-grade extremity-localized osteosarcoma from 6 cen-
ters in Sweden, 3 centers in Norway, and 2 centers in Finland, 
were treated according to the SSG XIV protocol (Figure 1). 
Eligibility criteria were age ≤ 40 years and no metastases evi-
dent at presentation, by mandatory use of chest CT and whole-
body bone scintigraphy. The primary tumor was assessed by 
conventional radiographs, technetium 99-MDP bone scan, 
MRI scan of the entire bone involved, and additional CT scan 
when needed. The diagnosis of osteosarcoma was confirmed 
by open biopsy. The SSG pathology panel reviewed all cases 
and agreed on diagnosis, subtype, and malignancy grade. 8 
patients were excluded due to metastatic disease (n = 6), a 
revised diagnosis of clear cell sarcoma (n = 1), or malignant 
fibrous histiocytoma (n = 1), thus making 63 patients (40 
males) eligible for this analysis (Table). The median age at 
diagnosis was 15 (8–39). Primary tumor localizations were 
femur (n = 34), tibia (n = 15), humerus (n = 6), fibula (n = 4), 
radius (n = 2), and other (n = 2). The tumor volume measure-
ments were based upon MRI scans using the ellipsoid formula 
V = 0.52 × abc.
Chemotherapy
Chemotherapy consisted of 2 cycles of methotrexate (MTX; 
12 g/m2), doxorubicin (ADM; 75 mg/m2), and cisplatin (CDP; 
90 mg/m2) (MAP) preoperatively and 3 cycles postoperatively 
(Figure 1). Poor histological responders continued to receive 3 
courses of ifosfamide (IFO; 10 g/m2) as an add-on treatment. 
With good hematological tolerance, the protocol advocated 
escalation of the IFO dose by 20% for the next course. MTX 
was administered in a 4-hour infusion with 11 doses of leu-
covorin (folinic acid) as rescue (8 mg/m2) every sixth hour, 
beginning 24 h after starting the MTX infusion (Ferrari et al. 
2005). CDP was delivered as a 48-h continuous infusion intra-
venously and was followed by ADM given as a 4-hour con-
tinuous infusion. IFO, in combination with an equal amount of 
mesna, was administered as continuous infusion at a dose of 2 
g/m2/day for 5 consecutive days. Postoperative chemotherapy 
was scheduled to begin 1 week after surgery. All drugs were 
given as single agents. 
Figure 1. Outline of treatment in the SSG XIV protocol.
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Complete blood counts, renal function, and liver function 
were monitored before each chemotherapy cycle. No dose 
reduction was allowed, and if the absolute granulocyte count 
was equal to or less than 1000/µL (500 for MTX cycles), 
and/or the platelet count was equal to or less than 100.000/
µL (60.000 for MTX cycles), chemotherapy was delayed until 
recovery. After each cycle, the blood count was monitored 
twice weekly starting on day 7 from the start of chemotherapy. 
G-CSF support was given according to the ASCO guidelines 
(1994).
Surgery and histological response assessment
The type of surgery was chosen depending on the size and the 
location of the tumor, neurovascular involvement, and skeletal 
maturity. For local excision, it was mandatory that preopera-
tive staging gave the possibility of achieving adequate surgi-
cal margins. The type of reconstruction was chosen according 
to tumor location and extension, patient age, and preferences. 
After surgery, the surgical margins were assessed according to 
Enneking as radical, wide, marginal, or intralesional. The grad-
ing of histological response analysis was done with a modified 
2-grade Huvos scale (Huvos et al. 1977). Good response was 
defined as < 10% of examined tumor area revealing unques-
tionable viable tumor and no single area of unaffected viable 
tumor exceeding 2.5 mm in its largest diameter. Poor response 
was defined as either of the 2 criteria being unfulfilled. The 
initial pathological evaluation at each institution determined 
the postoperative chemotherapy. Sections from each patient’s 
tumor were reviewed for histological response by the SSG ref-
erence pathology panel.
Response criteria and statistical analysis 
Metastasis-free survival was calculated from the date of 
diagnosis of the primary tumor until the date of diagnosis of 
distant metastases or last follow-up. Event-free survival was 
calculated from the date of diagnosis until the date of distant 
metastases, local recurrence, treatment-related death, or last 
follow-up. Sarcoma-related survival was calculated from the 
date of diagnosis until death from osteosarcoma, from treat-
ment-related causes, or last follow-up. For statistical analysis, 
SPSS for Windows release 15.0 was used. The Kaplan-Meier 
method was used for survival analysis and 95% confidence 
intervals (CIs) were calculated. Survival distributions were 
compared by the log-rank test.
Results
Clinicopathological data are listed in the Table.
 
Compliance 
2 patients did not receive neoadjuvant chemotherapy, as one 
was in need of prompt surgical treatment and the other had 
a preoperative diagnosis of chondrosarcoma, which was later 
revised to high-grade osteosarcoma. 1 patient was treated 
postoperatively according to a different chemotherapy pro-
tocol, as decided by the treating physician. The median time 
from start of chemotherapy to surgery was 80 days, which 
represents a median delay of 17 days to protocol. The median 
duration of treatment was 219 days in good responders and 
275 days in poor responders, representing median delays of 
65 days for good responders and 67 days for poor respond-
ers. Data on chemotherapy compliance were available for 57 
patients. Of these, 50 patients received all 5 courses of CDP/
ADM, of whom 37 were given with no dose reduction. 2 
patients received only 2 courses, one due to early death and 
the other due to change in postoperative therapy as mentioned 
above. 5 patients received only 4 courses due to toxicity. 47 
of the 63 patients received all 10 courses of MTX. No dose 
reduction was recorded for MTX. Regarding IFO courses, 23 
of the 26 patients received all 3 courses with a dose reduction 
for 3 of the patients. Overall, 49 of the 57 patients included in 
the compliance analyses received 4 or more courses of CDP/
ADM and 8 or more courses of MTX.
Toxicity
Detailed toxicity data were available for 48 of the patients, 
and included 233 ADM/CDP courses in total. One third of 
the CDP/ADM courses and one quarter of the IFO courses 
were followed by grade-IV leukopenia. 10 of the patients did 
not experience any episode of grade-IV leukopenia. Regard-
ing platelet toxicity, 28% of the CDP/ADM courses were fol-
lowed by grade-IV thrombocytopenia and 31% of patients 
received platelet transfusion. For the IFO courses, only 1 out 
of 81 recorded courses was followed by grade-IV toxicity and 
no platelet transfusion was given. 9 patients experienced a 
mild to moderate renal impairment, mainly after MTX admin-
istration. This caused changes in the planned schedule for 1 
patient. None of these patients required dialysis.
We experienced 3 treatment-related deaths, all related to 
acute toxicity from chemotherapy. 1 patient (a boy of 8 years) 
developed neutropenic fever and septic shock after comple-
tion of preoperative therapy. 1 patient (a good responder) 
developed typhlitis and septicemia after the first postopera-
tive cycle of chemotherapy, and 1 patient (a poor responder) 
developed septic shock in association with the last cycle of 
postoperative ADM/CDP. In addition, 2 cases of life-threat-
ening toxicity were observed. A male patient (aged 21) stayed 
10 days at the intensive care unit after completion of preoper-
ative chemotherapy due to development of severe enterocoli-
tis in combination with grade-IV neutropenia and thrombocy-
topenia. The second case was a girl (aged 15) who developed 
grade-IV cardiotoxicity before the third course of IFO, and 
who was in need of prompt medical treatment. Her cardiac 
function is not fully normalized more than 3 years after the 
end of therapy, and the patient is permanently in need of med-
ical treatment. 214  Acta Orthopaedica 2011; 82 (2): 211–216
Surgery and local control 
53 of the patients were treated with limb salvage surgery (n = 
45) or rotationplasty (n = 8). 8 patients had amputations and 
2 patients were not operated due to early progression or toxic 
death. 39 of the operated patients obtained wide margins. 2 
patients, both poor responders, developed local recurrence at 
18 and 29 months after diagnosis. One had a wide surgical 
margin and the other had a marginal one. 1 of these patients 
later developed distant metastases and died 30 months after 
diagnosis. The other was treated with amputation (lower 
extremity), and is alive in second complete remission 64 
months from diagnosis and 35 months from local recurrence. 
The 5-year projected local recurrence-free survival is 96% 
(CI: 91–100).
Histological response and postoperative chemo-
therapy
Histological response was documented in 59 patients. As 
mentioned above, 2 patients were treated with amputation. 
1 patient had toxic death before surgery and one patient was 
never operated due to early disease progression. According 
to the primary response assessment that decided the post-
operative therapy, 29 patients achieved a good response and 
30 patients had a poor response. Information on postopera-
tive chemotherapy was lost for 1 patient (a poor responder). 
For the remaining 58, in 1 poor responder alpha-interferon 
was exchanged for IFO as salvage therapy, 1 poor responder 
received postoperative chemotherapy according to another 
protocol, and 1 poor responder died before the start of IFO. 
Thus, 29 patients received unchanged MAP postoperatively 
and 26 patients underwent salvage therapy with addition of 
IFO according to protocol. In 5 of 26 patients, the IFO dose 
was escalated by 20% for the second and/or third cycle. No 
patient had a second escalation of the IFO dose. The pathology 
review process changed the response assessment in 4 patients, 
in 3 from good to poor response and in 1 from poor to good 
response. Thus, according to definite response assessment by 
review pathologists, 27 of the patients had a good response 
and 32 had a poor response.
 
Survival and post-relapse outcome
With a median follow-up time of 77 (16–107) months for 
survivors, 45 patients are alive and in complete remission. 
Excluding 1 patient who was lost to follow-up at 16 months, 
the follow-up time for survivors was at least 4 years. 1 patient 
died, not related to osteosarcoma or actual treatment. The esti-
mated sarcoma-related survival at 5 years is 76% (CI: 65–87) 
(Figure 1). 19 patients experienced a metastatic relapse and 
the projected metastasis-free survival at 5 years is 70% (CI: 
58–82) (Figure 2). The median time from diagnosis to relapse 
was 20 months, and 18 relapses occurred within 30 months 
from diagnosis—and in 1 patient, 92 months from diagno-
sis. The event-free survival at 5 years was 65% (CI: 53–77), 
including 1 local recurrence and 3 treatment-related deaths 
in addition to 19 metastatic relapses. 5-year metastasis-free 
survival by postoperative chemotherapy (n = 55) was 89% (n 
= 29) for patients receiving unchanged MAP and 48% (n = 
26) for patients receiving addition of IFO (log rank test, p = 
0.003). Five-year metastasis-free survival by definite histo-
logical response (n = 59) was 89% (n = 27) for good respond-
ers and 54% (n = 32) for poor responders (log rank test, p = 
0.01). For the definitely poor responders who received salvage 
therapy with IFO (n = 24), the 5-year metastases-free survival 
was 48%. 
Metastasis-free survival revealed no differences between 
sexes, with 5-year survival of 68% for males and 73% for 
females (log rank test, p = 0.7). Of the 19 patients who devel-
oped distant metastases, 13 had lung metastases only, 3 had 
lung metastases in combination with metastases at other sites, 
2 had bone metastases only, and no information was available 
for 1 patient. Treatment of relapse was not defined by protocol 
and it varied between centers according to previous therapy; 
15 patients were treated using second-line surgery and surgery 
only was offered to 7 patients. Second-line chemotherapy was 
given to 7 patients and 1 patient received interferon adjuvant 
to surgery. 14 patients achieved a second complete remission 
and 6 of those are alive 16–74 months after relapse. All 5 
patients who did not have a second complete remission died 
of osteosarcoma.
Discussion 
The characteristics of the patients in the present SSG XIV 
study are similar to those in the SSG VIII and ISG/SSG 1 stud-
ies, and the survival data are similar to those in other osteo-
sarcoma trials (Saeter et al. 1991, Fuchs et al. 1998, Smeland 
et al. 2003, Ferrari et al. 2005, Meyers et al. 2005). The SSG 
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XIV 5-year sarcoma-related survival was 76% and metastasis-
free survival was 70%, as compared to 64% and 55% in the 
SSG II study (Saeter et al. 1991), 74% and 63% in the SSG 
VIII study (Smeland et al, 2003), and 72% and 60% in the 
ISG/SSG 1 study (Ferrari et al. 2005).
Metastasis-free survival probably best reflects the efficacy 
of the chemotherapy regimen and, interestingly, the metas-
tasis-free survival was higher in SSG XIV using a 3-drug 
regimen for all patients, with addition of IFO only for poor 
responders, as compared to the ISG/SSG 1 trial that used all 4 
drugs up-front.  This may reflect the possibility that not only 
cumulative doses but also the dose intensity of each drug is 
important (Bruland and Pihl 1997).
In previous trials, the amputation rates were much higher: 
e.g. the SSG II study had an amputation rate of 77% and a 
local recurrence rate of 5%. The fraction of SSG XIV patients 
that received limb salvage surgery or rotationplasty (0.8) was 
comparable to that in the ISG/SSG 1 trial (0.9%) with a local 
recurrence rate of 3% and 5%, respectively. Thus, it seems 
appropriate to conclude that in a multi-institutional setting 
more than four-fifths of the patients can be offered limb-sal-
vage surgery or rotationplasty without altering the risk of local 
recurrence. The low number of local recurrences in SSG XIV 
may also have contributed to the favorable sarcoma-related 
survival rate, since local recurrences are often followed by 
distant metastases and death from disease (Bacci et al. 2007). 
In SSG XIV, 2/63 patients had a local recurrence in contrast to 
8/113 in the SSG VIII study. 
Another issue that may influence the overall results is stage 
migration due to the consistent use of high-resolution CT 
chest scans. Patients with metastases at presentation have a 
worse prognosis, and for the 6 patients who were not included 
in this analysis because of metastatic disease at presentation 
(but who were treated according to the protocol), 4 died from 
their disease. 
Treatment of metastatic relapse was not defined by the pro-
tocol, but the data reveals a substantial practice of metasta-
sectomy. 14 of 19 relapsed patients had a second complete 
remission and, of these, six are alive. This is comparable with 
published results from other intergroups and SSG’s own expe-
rience (Saeter et al. 1995, Ferrari et al. 2003, Kempf-Bielack et 
al. 2005). In SSG VIII, three quarters of the relapsed patients 
received second-line surgery and the overall survival at 5 years 
from relapse was 21%; all were in the group that had a second 
complete remission (Smeland et al. 2003). 
The preoperative chemotherapy in this protocol was similar 
to that in SSG VIII. However, the percentage of good respond-
ers differed—46% in SSG XIV and 58% in SSG VIII. This 
may reflect the slightly modified pathology assessment crite-
ria defined by this protocol.
The difference in metastasis-free survival between good and 
poor histological responders in the current report was 42%. 
For the patients with a definite assessment of poor histologi-
cal response who received additional IFO treatment, 5-year 
survival was 48%. With the limitation of a non-randomized 
design, and based on a univariate analysis only, the data show 
that the salvage strategy used in this protocol did not improve 
the prognosis of poor responders to that of good responders. 
Interestingly, the 5-year metastases-free survival for poor 
responders in the SSG VIII study that were salvaged by a post-
operative exchange of MAP (used preoperatively) to an ifos-
famide/etoposide combination showed a similar metastases-
free survival of 53% (Smeland et al. 2003). This may reflect an 
underlying chemoresistance, including one to IFO. The reason 
for the design chosen in SSG XIV was not to interfere with the 
dose intensity of MAP. This highlights the importance of the 
ongoing EURAMOS-1 study (Marina et al. 2010), which will 
address the salvage question in a randomized trial. Compared 
to the SSG XIV protocol, IFO is introduced earlier in the post-
operative regimen in EURAMOS-1. 
We recorded 3 treatment-related deaths in SSG XIV. The 
reported percentage of treatment-related death in previous 
SSG osteosarcoma trials was in the range of 1–3%: 3/113 
in SSG VIII and 1/57 in ISG/SSG I. 2 more cases of life-
threatening toxicities in the current trial, all due to acute 
chemotherapy-induced toxicity, emphasize the importance 
of organizing safe osteosarcoma care. The 4 cases with life-
threatening enterocolitis combined with neutropenic fever 
reported in SSG XIV contrast with the SSG VIII study, which 
used the same drugs at the same doses but with differences 
in administration of CDP and ADM. In SSG VIII, CDP was 
given as a 4-h infusion instead of the 48-h treatment in SSG 
XIV, and ADM was administered as a daily 4-h infusion at a 
dose of 25 mg/m2 for 3 consecutive days rather than the one 
4-h infusion at a dose of 75 mg/m2 used in SSG XIV. To our 
knowledge, there have no reports in the literature on more 
acute (or long-term) toxicity associated with a prolonged 
CDP infusion, as seen in SSG XIV. Regarding doxorubicin 
scheduling, a more prolonged infusion is associated with 
more acute mucocitis but less cardiotoxicity, and thus does 
not explain the increased intestinal toxicity observed in SSG 
XIV compared to SSG VIII (Bielack et al. 1996). One could 
speculate that the more frequent use of growth factor support 
in SSG XIV does not reduce the pattern of serious life-threat-
ening toxicity but rather shifts it. 
In conclusion, the outcome of the SSG XIV protocol com-
pares favorably with previous SSG trials and other published 
osteosarcoma trials. In this non-randomized trial, the salvage 
strategy with the use of high-dose IFO as an additional treat-
ment did not improve the outcome for poor responders to a 
level similar to that attained by good responders. 
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